XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
 3 Months Ended
Jul. 30, 2013
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   $ 60,827,000 $ 38,429,000  
Deferred Revenue   4,744,000   $ 15,857,000
Drug product revenue recognized   60,827,000 38,429,000  
Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   18,881,000 15,362,000  
Drug product revenue recognized   18,881,000 15,362,000  
Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   7,594,000 8,480,000  
Drug product revenue recognized   7,594,000 8,480,000  
AstraZeneca Agreements [Member] | Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   0 4,450,000  
Drug product revenue recognized   $ 0 4,450,000  
AstraZeneca Agreements [Member] | U.S./RoW [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Upfront, non-contingent, non-refundable and time-based payments $ 1,200,000,000      
Additional consideration based on net sales description   low 20% range    
Aggregate consideration received excluding drug product revenue   $ 439,000,000.0    
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   0 4,500,000  
Drug product revenue recognized   0 4,500,000  
AstraZeneca Agreements [Member] | China [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Upfront, non-contingent, non-refundable and time-based payments $ 376,700,000      
Aggregate considerations received   77,200,000    
AstraZeneca Agreements [Member] | China [Member] | Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   16,200,000 10,400,000  
Drug product revenue recognized   16,200,000 10,400,000  
Direct Sales [Member] | Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   2,658,000 4,956,000  
Drug product revenue recognized   2,658,000 4,956,000  
Direct Sales [Member] | China [Member] | Product Revenue, Net [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Total revenue   2,700,000 5,000,000.0  
Drug product revenue recognized   $ 2,700,000 $ 5,000,000.0